Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitour… Read more
Withuspharmaceutical Co.Ltd (330350) - Total Assets
Latest total assets as of September 2025: ₩140.92 Billion KRW
Based on the latest financial reports, Withuspharmaceutical Co.Ltd (330350) holds total assets worth ₩140.92 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Withuspharmaceutical Co.Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Withuspharmaceutical Co.Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Withuspharmaceutical Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Withuspharmaceutical Co.Ltd's total assets of ₩140.92 Billion consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩17.89 Billion | 0.0% |
| Accounts Receivable | ₩22.14 Billion | 16.4% |
| Inventory | ₩16.15 Billion | 12.0% |
| Property, Plant & Equipment | ₩49.24 Billion | 36.6% |
| Intangible Assets | ₩10.84 Billion | 8.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Withuspharmaceutical Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Withuspharmaceutical Co.Ltd's current assets represent 45.4% of total assets in 2024, a decrease from 77.7% in 2017.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, the same as 0.0% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 8.0% of total assets, an increase from 2.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 36.6% of total assets.
Withuspharmaceutical Co.Ltd Competitors by Total Assets
Key competitors of Withuspharmaceutical Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Withuspharmaceutical Co.Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Withuspharmaceutical Co.Ltd generates 0.76x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Withuspharmaceutical Co.Ltd generates $ 3.55 in net profit.
Withuspharmaceutical Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.92 | 1.84 | 3.64 |
| Quick Ratio | 1.43 | 1.32 | 3.25 |
| Cash Ratio | 0.00 | 0.35 | 0.00 |
| Working Capital | ₩33.59 Billion | ₩ 26.05 Billion | ₩ 53.67 Billion |
Withuspharmaceutical Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Withuspharmaceutical Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.0% |
| Total Assets | ₩134.69 Billion |
| Market Capitalization | $34.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Withuspharmaceutical Co.Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Withuspharmaceutical Co.Ltd's assets grew by 3.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Withuspharmaceutical Co.Ltd (2017–2024)
The table below shows the annual total assets of Withuspharmaceutical Co.Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩134.69 Billion | +2.99% |
| 2023-12-31 | ₩130.78 Billion | +9.54% |
| 2022-12-31 | ₩119.39 Billion | +0.35% |
| 2021-12-31 | ₩118.98 Billion | +12.05% |
| 2020-12-31 | ₩106.18 Billion | -0.78% |
| 2019-12-31 | ₩107.01 Billion | +40.28% |
| 2018-12-31 | ₩76.28 Billion | +10.53% |
| 2017-12-31 | ₩69.02 Billion | -- |